APOE and Alzheimer disease: Another desirable feature of CNP520 is that the drug had equivalent effects in ApoE4 carriers and non‐carriers, which is particularly important as the Generation Studies are enrolling participants who are at risk of developing AD based on the presence of ApoE4.